

Anti-Human CD30 FITC

Catalogue Number : 02411-50

RUO: For Research Use Only. Not for use in diagnostic procedures.

Product Information

Clone: Ber-H2

Format/Conjugate: FITC

Concentration: 5 uL (0.125 ug)/test

Reactivity: Human

Laser: Blue (488nm)

Peak Emission: 520nm

Peak Excitation: 494nm

Filter: 530/30

Brightness (1=dim,5=brightest): 3

Isotype: mouse IgG1, kappa

Formulation: Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, pH7.2.

Storage: Product should be kept at 2-8°C and protected from prolonged exposure to light.

Applications: FC

Description

The Ber-H2 monoclonal antibody specifically reacts with human CD30, a 120kDA type I transmembrane glycoprotein of the tumor necrosis factor receptor superfamily (TNFR) also known as the Ki-1 antigen. CD30 can elicit signals leading to either activation or apoptosis through interaction with CD30 ligand (CD30L). It is expressed by a subset of extrafollicular activated B and T cells, lung macrophages, activated NK cells, lymphomas, and endothelial cells. It is highly expressed on Hodgkins and Reed-Sternberg cells.

Preparation & Storage

The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.

Application Notes

The antibody has been analyzed for quality through the flow cytometric analysis of the relevant cell type. The antibody can be used at less than or equal to 5 µL per test. A test is the amount of antibody required to stain a cell sample in the final volume of 100 µL.

References

- 1.Schwartz, R., Gerdes, J., Durkop, H., Falini, B., Pileri, S., Stein, H. (1989). BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope.;Blood.;74(5), 1678-1689.
2. Beljaards, R. C., Meijer, C. J., Scheffer, E., Toonstra, J., Van Vloten, W. A., Van Der Putte, S. C., ... Willemze, R. (1989). Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients.;The American journal of pathology.;135(6), 1169.
3. Horie, R., Watanabe, T. (1998, December). CD30: expression and function in health and disease. In;Seminars in immunology;(Vol. 10, No. 6, pp. 457-470). Academic Press.